Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 11/03/2026

    Blood Marker for Alzheimer’s May also Be Useful in Heart and Kidney Diseases

    A certain blood protein regarded as an early indicator of Alzheimer’s disease also appears to play a role in other disorders. Researchers at DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen have found that elevated levels of phosphorylated tau protein (pTau) also occur in two lesser-known conditions that primarily affect the heart and kidneys.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-marker-alzheimers-may-also-be-useful-heart-and-kidney-diseases
  • Press release - 02/03/2026

    Novel therapy for Phelan-McDermid syndrome Drug development to be funded with up to 1.7 million euros

    An international team led by Professor Tobias M. Böckers from Ulm University Medical Centre has been awarded up to 1.7 million euros to develop a novel therapy for a rare, syndromic form of autism. The research project focuses on a gene whose loss of function can manifest itself in severe impairments in language, behaviour and everyday functions of those affected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-therapy-phelan-mcdermid-syndrome-drug-development-be-funded-17-million-euros
  • Press release - 19/02/2026

    Seeing cells in a new light

    Illuminating the tiniest details of living cells just got a major boost: Scientists at the Max Planck Institute for Medical Research have developed new markers that glow in the far-red range and are activated by light. They are stable, easy to control, and compatible with several super-resolution microscopy techniques, as outlined in a paper published in the journal Chem.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/seeing-cells-new-light
  • Press release - 17/02/2026

    Tracing Tumors in Cerebrospinal Fluid: A New Opportunity for Precision Diagnostics in Brain Tumors

    In a published scientific study, researchers have succeeded in accurately diagnosing common types of brain tumors in children and adolescents based on tumor-derived genetic material in cerebrospinal fluid. Until now, these so-called liquid biopsies were not capable enough for such reliable diagnostics. The international research team has therefore optimized a sequencing technique and developed an AI-based computational method. In a later step,…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracing-tumors-cerebrospinal-fluid-new-opportunity-precision-diagnostics-brain-tumors
  • Press release - 13/02/2026

    How pancreatic cancer prepares tumour environment Possible biomarker for earliest stage of development

    Even before a tumour in the pancreas becomes discernible, an activated cancer gene actively remodels its future environment and creates an inflammatory and immune-defensive microenvironment in which the carcinoma can grow. The scientists' study opens up new possibilities for developing personalised intervention strategies - before a difficult-to-treat tumour even develops.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-pancreatic-cancer-prepares-tumour-environment-possible-biomarker-earliest-stage-development
  • Press release - 06/02/2026

    nanodiag BW receives funding for second implementation phase

    nanodiag BW has received approval from the BMFTR for a further three-year implementation phase under the Clusters4Future initiative. With the approval of €15 million, the innovation network will be able to continue its work on nanopore-based diagnostic methods seamlessly from April 2026 onwards. The Baden-Württemberg Ministry of Economic Affairs, Labour and Tourism is supporting the cluster management through accompanying measures.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanodiag-bw-receives-funding-second-implementation-phase
  • Press release - 17/12/2025

    Improving cancer therapy with artificial organs DFG funds research training group "Org-BOOST" with around nine million euros

    Recreating tumour tissue in the laboratory as realistically as possible and developing new approaches for personalised cancer medicine: A total of 20 doctoral students in the life sciences and ten Medicine students will be researching this in the new "Organoid-Based mOdelling of Solid Tumours" research training group. They want to gain a better understanding of cancer and better predict the course of the disease and the effect of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/improving-cancer-therapy-artificial-organs-dfg-funds-research-training-group-org-boost-around-nine-million-euros
  • Press release - 16/12/2025

    Hummingbird Diagnostics Publishes Study on RNA Biomarker Methylation in Liquid Biopsies

    Hummingbird Diagnostics GmbH, a pioneer in harnessing blood-based small RNAs for early disease detection and characterization, today announced the publication of a new study in Nature Communications Medicine introducing an Oxford Nanopore Technologies (ONT)-based method for detecting small RNA modifications in blood.

    https://www.gesundheitsindustrie-bw.de/en/article/hummingbird-diagnostics-publishes-study-rna-biomarker-methylation-liquid-biopsies
  • Press release - 16/10/2025

    Sleep as the key to understanding ME/CFS

    The Federal Ministry of Research, Technology and Space (BMFTR) is supporting the “Sleep-Neuro-Path” research network with around 1.6 million euros. Coordinated by the Central Institute of Mental Health (CIMH) in Mannheim, a team of scientists is investigating the role of sleep-related biomarkers in the development of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sleep-key-understanding-mecfs
  • Press release - 23/09/2025

    Mutation in non-coding DNA worsens leukaemia prognosis Ulm study uncovers previously unknown disease-promoting mechanism

    Why is blood cancer particularly aggressive in some patients? Researchers at Ulm University Hospital have characterised a mutation in the so-called NOTCH1 gene that significantly influences the prognosis of chronic lymphocytic leukaemia (CLL). Remarkably, this mutation is located in the non-coding region of the gene – an area of DNA long considered less relevant for disease mechanisms.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mutation-non-coding-dna-worsens-leukaemia-prognosis-ulm-study-uncovers-previously-unknown-disease-promoting-mechanism
  • Press release - 04/09/2025

    Fraunhofer researchers develop innovative diagnostics for detecting antibiotic resistance in bacterial infections

    The rapid increase in antibiotic-resistant bacteria is one of the most pressing challenges facing global health. A new transatlantic Fraunhofer research project aims to counter these threats with an innovative diagnostic approach: a microfluidic rapid test system using carbon nanotubes (SWCNT) will make bacterial resistance visible in just a few minutes, significantly faster than conventional methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fraunhofer-researchers-develop-innovative-diagnostics-detecting-antibiotic-resistance-bacterial-infections
  • Press release - 12/08/2025

    Biomarkers for Brain Insulin Resistance Discovered in the Blood

    If the brain no longer responds properly to insulin (insulin resistance), this can lead to overweight, diabetes, and Alzheimer's disease. Researchers at the DZD in Potsdam and Tübingen have discovered small chemical modifications to genetic material (epigenetic changes*) in the blood that indicate how well the brain responds to insulin. These markers could help to detect insulin resistance in the brain – by means of a simple blood test.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biomarkers-brain-insulin-resistance-discovered-blood
  • Press release - 01/08/2025

    Early Pancreatic Cancer Detection

    Tumors of the pancreas seldom cause symptoms in their early stages. This means that in many cases, they are not diagnosed until late, when the chances of successful treatment are poor. A new non-invasive diagnostic method designed by Fraunhofer researchers is set to make it possible to detect this aggressive form of cancer early on with high accuracy, significantly improving the prognosis for treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/early-pancreatic-cancer-detection
  • Press release - 24/07/2025

    The origin of evil: stem cell-like cells are the reason for relapses of blood cancer in children and adolescents

    Stem cell-like leukemia cells are responsible for relapses in children and adolescents with a certain type of blood cancer, T-ALL. Researchers at the Hopp Children's Cancer Center Heidelberg (KiTZ), the Molecular Medicine Partnership Unit and the German Cancer Research Center were able to show this in a study. The results could help to overcome resistance in this form of blood cancer and prevent relapses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/origin-evil-stem-cell-cells-are-reason-relapses-blood-cancer-children-and-adolescents
  • Press release - 21/07/2025

    Cancer Cachexia: Liver Identified as Driver of Body Wasting

    Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected. This wasting syndrome, affects around half of all cancer patients. Researchers from Helmholtz Munich, in collaboration with Heidelberg University Hospital, the Technical University of Munich, and the German Center for Diabetes Research, have now identified a previously overlooked driver of cachexia: the liver.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-cachexia-liver-identified-driver-body-wasting
  • Press release - 18/07/2025

    Faster sepsis diagnosis through hyperspectral imaging and AI

    Sepsis is one of the most dangerous medical emergencies. The condition is the result of a misdirected immune response to an infection, which can quickly lead to organ failure and death. Every hour counts – but early detection is difficult. A new study from Heidelberg now presents an innovative approach: artificial intelligence (AI) and hyperspectral imaging of the skin enable immediate and non-invasive sepsis diagnosis directly at the bedside.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/faster-sepsis-diagnosis-through-hyperspectral-imaging-and-ai
  • Press release - 15/07/2025

    ERC funding for research into improved cancer immunotherapies

    With its Proof of Concept grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research results. Two scientists from the German Cancer Research Center (DKFZ) have now received this coveted funding for the second time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-research-improved-cancer-immunotherapies
  • Press release - 08/07/2025

    Five million euros for research into early cancer detection

    Investing in a healthier future: The HORNBACH Group is supporting the new National Cancer Prevention Center in Heidelberg with a donation of five million euros. In the future, a new laboratory will conduct research into more effective early detection and screening methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/five-million-euros-research-early-cancer-detection
  • Press release - 21/05/2025

    How aging changes the blood system in humans and mice

    The reservoir of blood stem cells shrinks with age. It becomes increasingly dominated by stem cells that produce immune cells associated with chronic inflammation. Almost all of the 60-year-olds studied show this change. The new discovery could help explain the chronic inflammation that occurs with age and makes us more susceptible to disease. It could also help identify early warning signs of unhealthy aging processes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-aging-changes-blood-system-humans-and-mice
  • Press release - 16/04/2025

    Hereditary Alzheimer’s: Blood Marker for Defective Neuronal Connections Rises Early

    Individuals with a genetic predisposition to Alzheimer’s disease show altered blood levels indicating damaged neuronal contacts as early as 11 years before the expected onset of dementia symptoms. This is evident in the levels of the protein “beta-synuclein”. An international team report these findings in the journal “Alzheimer’s & Dementia”. The biomarker studied here could potentially help to detect neurodegeneration at an early stage.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hereditary-alzheimers-blood-marker-defective-neuronal-connections-rises-early
  • Vicinity Bio: Optimisation of cancer diagnostics - 27/11/2024 Das Bild zeigt eine mikroskopische Aufnahme eines Gewebes. Die Aufnahme ist bunt und unterschiedliche Zelltypen lassen sich deutlich erkennen.

    Comprehensive histological diagnostics through high-dimensional imaging and artificial intelligence

    Microscopic examination of tissue samples is essential, particularly in tumour diagnostics. The Tübingen-based company Vicinity Bio leverages cutting-edge imaging technologies combined with machine learning to generate comprehensive datasets of individual cells from tissue sections. This approach not only helps identify more targeted therapies but also enhances our understanding of cellular functions and processes within tissues and tumours.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Comprehensive-histological-diagnostics-through-high-dimensional-imaging-and-artificial-intelligence
  • NMI project WOUNDSENS - 23/10/2024 electrospinning_WoundSens.jpg

    Wound monitoring using sensory nanofibres

    Monitoring the condition of chronic, non-healing wounds requires wound dressings to be changed at short, regular intervals. In the EU-funded WOUNDSENS project, researchers at the NMI in Reutlingen are using electrospinning to produce novel types of wound dressings. These consist of biosensory fibres that send information about the condition of the wound to the outside, thereby improving inflammation detection.

    https://www.gesundheitsindustrie-bw.de/en/article/news/wound-monitoring-using-sensory-nanofibres
  • Press release - 18/09/2024

    Future cluster QSens starts the second round of funding

    In the “Cluster4Future” QSens of the Universities of Stuttgart and Ulm, scientists, companies and start-ups are researching quantum sensors with a wide range of potential applications. The Federal Ministry of Education and Research is funding QSens for a further three years as part of “Clusters4Future”.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/future-cluster-qsens-starts-second-round-funding
  • TWYCE GmbH - 10/07/2024 A micrograph shows how two T cells attack two tumour cells.

    Better immune response against prostate cancer thanks to new bispecific antibodies

    TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/better-immune-response-against-prostate-cancer-thanks-new-bispecific-antibodies
  • Press release - 05/07/2024

    Outstanding ideas – new imaging processes for cancer diagnostics and nanopropellers for ocular gene therapy

    The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-ideas-new-imaging-processes-cancer-diagnostics-and-nanopropellers-ocular-gene-therapy

Page 1 / 3

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search